Biotech entity
All 1 tracked stories fall under one category: pharma. Coherus BioSciences is most often covered alongside Amgen, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Coherus BioSciences, all published on March 8, 2026.
Last mentioned: Mar 8, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Coherus BioSciences is most often covered alongside Amgen, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Coherus BioSciences, all published on March 8, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Coherus BioSciences. Shared-story counts are live from our verified record — not editorial picks.
Coherus BioSciences is set to report Q4 2025 earnings as it completes its strategic transition into a pure-play oncology firm. Investors are focused on the commercial ramp of Loqtorzi and the market share recovery of the Udenyca franchise following the launch of its Onbody injector.
Coherus BioSciences is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
